|
|
|
|
Vol. 56, Issue 3, 515-525, September 1999
Department of Human Oncology, Medical School, University of Wisconsin, Madison, Wisconsin
| |
Summary |
|---|
|
|
|---|
Okadaic acid (OA), a toxin from the black sponge Halicondria okadai, is a specific inhibitor of serine/threonine protein phosphatases 1 (PP1) and 2A (PP2A). OA is a tumor promoter but also induces apoptosis in some tumor cell lines. In this study, we determined whether ras mutation and/or p53 status are characteristics associated with the cell's sensitivity to the induction of apoptosis by OA. Several cell lines that differed in ras and p53 mutations were treated with OA (10-100 nM). At 24 to 48 h after treatment, the percentage of cells undergoing apoptosis was quantitated. The cell lines with mutations in either H-ras (human bladder carcinoma cell line T24 and mouse keratinocyte cell line 308), or K-ras (human colon carcinoma cell lines DLD-1 and HCT116; human prostate cancer cell lines LNCaP and PC-3; human lung cancer cell lines Calu-6 and SKLU-1; and human pancreatic cancer cell line MIAPaCa2) were more sensitive to OA-induced apoptosis (3- to 10-fold) than the cell lines that lacked the ras mutation (mouse epidermal cell lines C50 and JB6; murine fibroblast cell line NIH3T3; human colon cancer cell line HT29; human kidney epithelial cell line Hs715.K; and human pancreatic cancer cell line Bx-PC3). Similarly, using isogenic cell lines we found that overexpression of mutated H-ras in NIH3T3 and in SV40 immortalized human uroepithelial cells (SVHUC) enhanced their sensitivity to undergo apoptosis in response to OA treatment. The T24, DLD-1, SKLU-1, Calu-6, and MIAPaCa2 cell lines express mutated p53. The SVHUC as well as their ras-transfected counterparts have inactive p53 due to complex formation between large "T" antigen and p53. Taken together, these results imply that OA-induced apoptosis may involve a p53-independent pathway. The transfectants (NIH3T3-ras and SVHUC-ras), which express mutated H-ras, have up-regulated PP2A activity. OA treatment inhibited in vivo the levels of PP1 and PP2A activity, and induced apoptosis in SVHUC-ras and other cell lines. We conclude that OA-induced cell death pathway in ras-activated cell lines may involve a cross talk between PP1 and PP2A and ras signaling pathways. In light of the present results, the current theory that OA promotes mouse skin tumor formation by selective expansion of initiated cells that harbor ras mutations needs reevaluation.
| |
Introduction |
|---|
|
|
|---|
The
reversible phosphorylation of proteins, catalyzed by protein kinases
and protein phosphatases (PP), is the key mechanism for the regulation
of diverse cellular functions (Cohen, 1997
). The serine/threonine PPs
are encoded by the PPP and PPM gene families. The PPP family
includes PP1, PP2A, and PP2B (calcineurin and
Ca2+-calmodulin-regulated PP), whereas the PPM family
consists of Mg2+-dependent PPs, which include
PP2C and pyruvate dehydrogenase phosphatase. The catalytic subunit of
PP1 (PP1c) is a 37-kDa protein that forms heterodimers with several
regulatory units. PP2A is a family of trimeric holoenzymes composed of
a 36-kDa catalytic subunit (PP2Ac) bound to a constant regulatory
subunit of 65 kDa (PR654) and one of the number of variable subunits
(52-130 kDa). The PPP family of PPs are involved in many cellular
processes including glycogen metabolism, calcium transport, muscle
contraction, protein synthesis, regulation of cell cycle, and RNA
splicing (Cohen, 1997
; Fischer, 1997
). A number of naturally
occurring agents such as okadaic acid (OA), microcystin, tautomycin,
and calyculin A (Fujiki and Suganuma, 1993
; Cohen, 1997
), have been reported to inhibit the members of the PPP family (Table
1).
|
|
|
|
|
|
OA is the most commonly used inhibitor of PPs 1 and 2A.
OA,
a toxic polyether compound of a C38 fatty acid,
was first
isolated from two sponges, Halicondria okadai and H. melanodocia (Fujiki and Suganuma, 1993
). OA is a mouse skin tumor
promoter that stimulates gene expression (Rosenberger and Bowden, 1996
)
and has the ability to induce a pseudomitotic effect. OA has also been
shown to induce apoptosis in several cell lines such as human breast
cancer (Kiguchi et al., 1994
), retinoblastoma (Inomata et al. 1995
),
osteoblastic (Morimoto et al., 1997
), rat kidney epithelial (Davis et
al. 1996
), neuroblastoma, and rat pituitary adenoma cell lines (Tergau
et al., 1997
). However, it is unclear whether OA-induced apoptosis is
correlated to a common genetic abnormality present in various cell
types.
|
|
|
|
|
|
|
|
|
|
The mutations in the ras genes are among the most widely
observed genetic changes during tumorigenesis in humans (Bos,
1989
; Vojtek and Der, 1998
). Approximately 30 to 40% of all human
cancers elicit mutations in the ras allele (Bos, 1989
).
Ras, a 21-kDa membrane-associated GTP-binding protein,
regulates diverse extracellular signals controlling cellular processes
(Vojtek and Der, 1998
; Marshall, 1995
). The mammalian ras
gene family consists of four homologous members (H-ras,
K-ras, N-ras, and R-ras)
and each encodes a 21-kDa protein (McCormick, 1995
). A series of
proteins involving protein-protein interactions as upstream molecules
are responsible for the control of ras activation.
Ras activation, for its downstream signaling, involves its
association with the plasma membrane. The association of ras
with the outer plasma membrane is mediated by a 15-carbon farnesyl
group that is covalently linked to ras (Lerner et al.,
1997
). The plasma membrane location of ras switches ras protein from the inactive GDP-bound to the active
GTP-bound state. Mutations in ras genes localize in the
N-terminal region controlling GTP-binding. Mutations lock
ras in the GTP-bound state. Guanosine nucleotide exchange
factors promote the formation of active GTP-bound forms of
ras, whereas GTPase activating proteins promote the
formation of the inactive GDP-bound form of ras. The mammalian ras gene family acquires oncogenic activity by
somatic mutations predominantly localized to amino acids 12, 13, and 61 (Vojtek and Der, 1998
). The role of ras oncogenes in
tumorigenesis has been well documented in various animal models
(Stanely, 1995
). Mutations in one of the three ras genes has
been associated with specific human cancers. Transitional cell
carcinoma of human urinary bladder have predominately H-ras
mutations, whereas 95% of pancreatic adenocarcinomas, and other human
tumors including colon cancers contain mutation in the K-ras
gene. N-ras mutations have been observed in some cases of
acute myeloid leukemia (Boss, 1989
).
We determined whether chronic activation of ras due to
mutations contributes to the cell's sensitivity to the induction of apoptosis by OA. We present data indicating that 1) cell lines that
have ras mutation (H or K), irrespective of p53 status (von Kleist et al., 1975
; Taparowsky et al., 1982
; Strickland et al., 1988
;
Shirasawa et al., 1993
; Pergolizzi et al., 1993
; Aoki et al., 1997
),
can be induced to undergo apoptosis by treatment with the inhibitors of
PP1 and PP2A; 2) the H-ras mutation up-regulated the levels
of PP2A activity; and 3) OA-induced apoptosis accompanied inhibition of
ras-induced levels of PP2A activity.
| |
Materials and Methods |
|---|
|
|
|---|
Materials
OA was purchased from Alexis Laboratories (San Diego, CA). 12-O-Tetradecanoylphorbol-13-acetate (TPA) was purchased from Life Systems (Newton, MA). All other chemicals, including propidium iodide (PI), RNase H, dimethyl sulfoxide (DMSO), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) were purchased from Sigma Chemical Co. (St. Louis, MO). Phosphatase kit was purchased from Life Technologies/BRL (Gaithersburg, MD). Annexin V-staining kit was purchased from Clonetech (Palo Alto, CA). Anticyclin D1 was obtained from Santa Cruz Biotechnology, (Santa Cruz, CA). Anticyclin B1 was from Pharmingen (San Diego, CA).
Cell Lines
NIH3T3 cells, stably transfected with either E/J-ras or the neoexpression vector, were obtained from Dr. Terry Oberley, Department of Pathology, Veterans Administration Hospital, University of Wisconsin (Madison, WI). Human uroepithelial cell (UEPC) lines (SVHUC and SVHUC-ras) were obtained from Dr. Catherine Reznikoff, Department of Human Oncology, University of Wisconsin (Madison, WI). Human pancreatic ductal adenocarcinomas cell lines [BxPC3 and MIAPaCa2; originally from the American Type Culture Collection (Rockville, MD)] were obtained from Dr. Pamela L. Crowell, Department of Biology, Indiana University-Purdue University at Indianapolis (Indianapolis, IN). BxPC3 cells were cultured in RPMI 1640 containing 10% fetal bovine serum (FBS). The MIAPaCa2 cells were grown in Dulbecco's modified Eagles' medium (DMEM) containing 10% FBS. Lung cancer cell lines (Calu-6 and SKLU-1) were obtained from Dr. Joan Schiller, University of Wisconsin (Madison, WI) and were grown in MEM medium supplemented with 8% FBS. Colon carcinoma cell lines DLD-1 and COLO 201 were maintained in RPMI 1640 supplemented with 10 and 20% FBS, respectively, whereas HCT116 and HT29 cell lines were maintained in DMEM medium supplemented with 10% FBS. Human prostate cancer cell line PC3 was cultured in RPMI 1640 medium supplemented with 5% FBS. T24 cells were maintained in MacCoys 5A medium supplemented with 10% FBS. The LNCaP and NIH3T3 cells were maintained in DMEM supplemented with 5% FBS. SVHUC and SVHUC-ras and mouse keratinocytes cell lines 308 and C50 ]provided by Dr. Jill Pelling, University of Kansas Medical Center (Kansas City, KS)], were cultured in Ham's F12 medium supplemented with 250 U/ml insulin, 5 µg/ml Transferrin, 15 mM dextrose, 0.1 mM nonessential amino acids, 1 µg/ml hydrocortisone, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 1% FBS. Mouse epidermal cell line JB6 ]provided by Dr. Nancy M. Colburn, Cell Biology Section, Laboratory of Viral Carcinogenesis, National Cancer Institute (Frederick, MD)] was maintained in MEM containing 5% FBS, whereas the normal human kidney cell line HS 715.K was grown in the above medium with 10% FBS.
Cell Treatments
The cells were allowed to grow in their respective media until they were 70% confluent. Stock solution of OA was prepared in ethanol and was further diluted in DMSO. Cells were treated with various concentrations of OA. Control dishes were treated with the vehicle DMSO (final concentration: <0.1%).
Cell Viability Assay
The viability of the cells were determined using the MTT assay
(Mosmann, 1983
).
Apoptosis Assays
The cells undergoing apoptosis were identified and quantitated as follows.
Phase-Contrast Microscopy. The cells exhibiting characteristic morphological features associated with apoptosis were viewed under a microscope with a 40× objective and then photographed.
Flow Cytometric Analysis.
At appropriate times after
treatment, the cells were harvested by trypsin-EDTA treatment, washed
twice with ice-cold PBS and subsequently stained with antibody to
Annexin V-fluorescein isothiocyanate (FITC) and PI. This dual staining
technique revealed the viable (annexin
V
/PI
], preapoptotic
[annexin V+/PI
],
apoptotic [annexin
V+/PI+], and damaged
[annexin V
/PI+] cells
(Darzynkiewicz et al., 1996
). For analysis of cell cycle markers, the
harvested cell pellet was permeabilized using 0.25% Triton-X-100 solution in PBS for 5 min at 4°C. The cell pellet was washed and stained with anticyclin D1 and anticyclin B1 antibodies followed by incubation with the secondary antibody conjugated to FITC.
The cell pellet was washed and stained with staining solution
containing PI (5 µg/ml) and RNase H (200 µg/ml). This staining
technique allowed the immunochemical detection of cyclins in relation
to cell cycle position (DNA content) by mutiparameter flow cytometric
analysis. The percentage of cells undergoing apoptosis were also
quantitated by the method described by Darzynkiewicz et al. (1994)
. The
cell pellet obtained after harvesting the treated and untreated cells
was resuspended in ice-cold PBS and fixed in 95% ethanol. The fixed
cells were pelleted, resuspended in a PI staining solution, filtered
through a 40-µM pore nylon mesh, and analyzed using a
Becton-Dickinson FACStar plus flow cytometer with excitation 488 nM.
The DNA histograms elicited the
sub-G0-G1 cells as the
apoptotic peak in the various phases of the cell cycle.
DNA Fragmentation. To detect the DNA ladder typical of the apoptotic cells, DNA fragmentation analysis was performed. At approximate times after treatment, the genomic DNA was isolated (Gentra Systems, Minneapolis, MN) and subjected to agarose gel electrophoresis (1.8%). The DNA in the gel was visualized with the Fluoroimager SI (Molecular Dynamics, Sunnyvale, CA) after staining for 1 h with SYBR Green I nucleic acid gel stain (Molecular Probes, Eugene, OR).
PP Assay.
PP activity was assayed using
32P-labeled phosphorylase a as a
substrate which detects both PP1 and PP2A activities. We used the PP
kit supplied by Life Technologies/BRL. At appropriate times after
treatment, the cell pellet was homogenized in the extraction buffer
containing 20 mM Tris-HCI, pH 7.5, 5 mM EDTA, 10 mM EGTA, 15 mM
-mercaptoethanol, 0.25 M sucrose, 0.3% Triton X-100, 5 µg/ml
leupeptin, and 5 µg/ml aprotinin and centrifuged (40,000g) to give a soluble supernatant. The PP activity in the clear supernatant was determined by measuring the trichloroacetic acid-soluble counts released after incubation of the 32P-labeled
phosphorylase a in the cell extract. The PP activity was
linear up to assay times of 10 min and 5 µg protein of the cell
extract. Routinely, incubation for PP activity was carried out for 10 min with an extract containing 5 µg of protein as determined by the
Bio-Rad assay (Bio-Rad, Hercules, CA).
| |
Results |
|---|
|
|
|---|
Ras Mutation Imparts Sensitivity to Cells for Induction of Apoptosis by OA. To determine whether ras mutation is the key genetic event that is associated with the susceptibility of cells to undergo apoptosis in response to treatment with the PP inhibitor OA, we used genetically identical cell lines that differed only in the expression of mutated ras. In our initial experiments, we used NIH3T3 and human UEPC stably transfected with either pSV2-neo or PREJ ras (mutated c-H-ras with 12th codon mutation).
Subconfluent cultures of the parental, NIH3T3-neo, and NIH3T3-ras cells were treated with OA (10-40 nM) for a period of 24 or 48 h. The percentages of cells undergoing apoptosis were quantitated by flow cytometric analysis after staining of cells with PI (Fig. 1A). OA-induced apoptosis was observed only in NIH3T3-ras transfectants but not in parental NIH3T3 and NIH 3T3-neo cells at 24 h after OA treatment at 10, 20, or 40 nM (Fig. 1B). OA treatment at 40 nM for 48 h also resulted in a small increase in the apoptotic response of the parental NIH3T3 and NIH3T3-neo cell lines (Fig. 1C). The effects of OA on the morphology of NIH3T3 transfectants are shown in Fig. 2A. The addition of OA caused the cells to round up and detach from the substratum, which are preparatory events leading to apoptosis. The NIH3T3-ras cells were more sensitive to OA-induced detachment than the parental NIH3T3 and NIH3T3-neo cells (Fig. 2, A-F). OA-induced apoptosis of NIH3T3 cell lines was further confirmed by DNA fragmentation analysis. In this experiment, DNA was isolated from the parental NIH3T3-ras and neotransfected cells at 48 h after treatment with 20, 50, and 100 nM OA. As shown in Fig. 2G, internucleosomal cleavage was not observed in the parental and neotransfected NIH3T3 cell lines, whereas it was clearly observed in the ras-transfected NIH3T3 cells. The effects of OA treatment on the viability of the cells was analyzed by the MTT assay. As shown in Fig. 3, there appears to be a good correlation between the onset of apoptosis and the cell viability. The effect of OA on the induction of apoptosis in NIH3T3-ras cells was specific. As shown in Fig. 4, the potent mouse skin tumor promoter TPA failed to induce apoptosis in NIH3T3-ras cells. We also evaluated the cytotoxicity of a series of inhibitors of PP1 and PP2A (Table 1) toward NIH3T3-neo and NIH3T3-ras cell lines. The results are shown in Table 2. In these experiments, the NIH3T3 cells were treated with various concentrations of the indicated inhibitor (0, 0.01, 0.1, 1, 5, 10, 20, 50, and 100 nM), and at 48 h after treatment, cell viability was determined by the MTT assay. Shown in Table 2 are the concentrations which sacrificed 50% of the cells (IC50). Again, the NIH3T3-ras cells were more sensitive than the NIH3T3-neo cells to killing by the PP inhibitors; calyculin was the most cytotoxic among the PP inhibitors. In a separate experiment, we compared the cytotoxicity of OA with calyculin, dinophysitoxin, and OA tetracetate (OTA) on NIH3T3-ras cells. In this experiment (Fig. 5), apoptotic cells (sub-G0 cells) were determined by flow cytometric analysis of PI-stained cells. Calyculin and dinophysitoxin were more cytotoxic than OA. OTA, an inactive analog of OA, did not induce apoptosis in NIH3T3-ras cells (Fig. 5). We further compared the effects of OA on the induction of apoptosis in the isogenic UEPC (Pratt et al., 1992OA Induces Apoptosis in a Variety of Cell Types with Mutations in
Either H- or K-ras.
To further obtain evidence that
ras mutations determine a cell's sensitivity to OA-induced
apoptosis, we used several established cell lines with or without
ras mutations. As shown in Fig. 9, we observed a distinct
difference in the percentage of cells undergoing apoptosis between cell
lines with and without mutations in the ras oncogene. Cell
lines harboring mutations in either H-ras [e.g., T24
(Taparowsky et al., 1982
) and 308 (Strickland et al., 1988
) cells or in
K-ras (DLD1 and HCT116; Shirasawa et al., 1993
); PC3 and
LNCaP (Pergolizzi et al., 1993
); Calu-6 and SKLU-1 (Lehman et al.,
1991
); and MIAPaCa2 (Aoki et al., 1997
)] were more sensitive to OA-induced apoptosis (Fig. 9) than cell lines with wild-type ras oncogene [mouse epidermal cell lines C50, and JB6 (Sun
et al., 1993
); murine fibroblast cell line NIH3T3, human kidney
epithelial cell line Hs715.K, human UEPC line SVHUC human pancreatic
cancer cell line BxPC3 (Aoki et al., 1997
); and human colon cancer cell line HT29 (von Kleist et al., 1975
)].
OA-Induced Apoptosis Is Independent of p53 Status.
The tumor
suppressor p53, a nuclear phosphoprotein, plays a key role in the
induction of apoptosis. Post-translational modification by
phosphorylation of p53, mediated by several kinases, is essential for
its transcriptional activity (Mowat, 1998
). p53 is dephosphorylated by
PP1 and PP2A. The findings that OA has been shown to induce hyperphosphorylation of p53 (Yatsunami et al., 1993
) prompted us to
determine whether OA-induced apoptosis involves a p53-dependent pathway. In these experiments, we determined the ability of OA to
induce apoptosis in various cell lines with altered p53 status. At
first we determined the effects of OA on the induction of apoptosis in
SVHUC cells. SV40 encodes two proteins, large "T" antigen and "t" antigen. The large "T" antigen complexes with p53 and pRb family of proteins (Kao et al., 1993
). As shown in Fig. 6, OA-induced apoptosis in SVHUC in the absence of active p53 due to complex formulation with the large T antigen. We also found that cell lines
with or without mutations in p53 were susceptible to OA-mediated apoptosis (Fig. 9). Cell lines sensitive to OA-induced apoptosis included the prostate cancer lines PC3 and LNCaP. PC3 is androgen independent and is defective for both its alleles for the p53 gene,
whereas LNCaP is androgen sensitive and expresses the wild-type p53
gene (Israel et al., 1995
). Human bladder transitional carcinoma T24
cells carry an inframe deletion of tyrosine 126 in the p53 gene (Cooper
et al., 1994
). The colon cancer cell line HCT 116 expresses wild-type
p53 gene (Take et al., 1996
), whereas DLD-1 cells harbor a
mutation at position 241 (resulting a change from serine to
phenylalanine) in p53. The lung cancer cell line Calu-6 has mutations
at positions 196 and 213 whereas SKLU-1 cells exhibits mutation at
position 193 in the p53 gene. These results imply that OA-induced
apoptosis may involve a p53-independent pathway.
OA-Induced Apoptosis Accompanies Changes in Cell Cycle
Progression.
Because OA has been reported to induce the
hyperphosphorylation of cell cycle regulator proteins pRb and p53
(Yatsunami et al., 1993
), we determined whether OA-induced apoptosis
accompanies alterations in the cell cycle profile. Asynchronously
growing NIH3T3 parental, NIH3T3-ras, and NIH3T3-neo cells
were treated with 20 nM OA for 48 h, whereas SVHUC and
SVHUC-ras cells were treated with 20 nM OA for 24 h.
Both cell lines were stained with PI to determine the percentage of
cells in various phases of the cell cycle. The NIH3T3-ras
and SVHUC-ras cells treated with OA for 48 h displayed
a decrease in the G0-G1
phase of the cell cycle accompanied with an increase in the
sub-G2-M phase of the cell cycle as well as in
the sub-G0-G1 phase of the
cell cycle. The parental NIH3T3, the neotransfected NIH3T3 cells and
SVHUC cells did not reveal a distinct G2-M block
in their cell cycle progression (Table 3).
H-Ras Mutation Up-Regulates PP2A Activity.
A
possibility was explored to determine whether ras mutations
result in alterations in the basal PP1 and PP2A activities. In this
experiment (Fig. 11), the indicated cell lines were grown to
subconfluency and then were used to assay PP activity. PP2A and PP1
activities were distinguished by their sensitivity to 2 and 20 nM OA,
respectively (Huang et al., 1995
; Murata et al., 1996
). The PP1 and
PP2A activities were detected, although at different levels, in all the
cell lines evaluated. A novel observation is the finding that
H-ras mutation leads to an increase in the PP2A activity. As
shown in Fig. 11, NIH3T3 and human UEPCs after transfection with the
mutated H-ras displayed an increase in PP2A activity. It is
noteworthy that SVHUC, which are immortalized after transfection with
the wild-type SV40, which has both large T and small t antigens (Pratt
et al., 1992
), had reduced or no PP2A activity. This is because of the
fact that small t antigen specifically inhibits PP2A activity (Yang et
al., 1991
; Howe et al., 1998
). As shown in Fig. 10,
SVHUC-ras up-regulated PP2A activity. Similar results were
observed in other H-ras transfected cell lines (Fig. 11).
| |
Discussion |
|---|
|
|
|---|
Our results that show that the cell lines that harbor
ras mutations are more sensitive than cell lines with
wild-type ras to OA-induced apoptosis, were
unexpected. OA is a mouse skin tumor promoter (Fujiki and
Suganuma, 1993
). A majority of the mouse skin papillomas and
carcinomas, elicited by initiation with
7,12-dimethylbenz[a]anthracene and by promotion with TPA, contain a
point mutation (A to T) in the Ha-ras oncogene at condon 61 (Pelling et al., 1988
; Fujiki et al., 1989
; Kim et al., 1997
).
Similarly, Fujiki et al. (1989)
reported similar codon 61 mutations in
the Ha-ras gene in mouse skin tumors developed by initiation
with 7,12-dimethylbenz[a]anthracene and promotion with OA class tumor
promoters (OA, dinophysistoxin-1, and calyculin A) and TPA-type tumor
promoters (teleocidin and aplysiatoxin). These results led to the
current hypothesis that tumor promoters selectively cause the clonal
expansion of a population of initiated cells, which harbor
Ha-ras mutations, to form skin papillomas and carcinomas.
Our cell lines, which express Ha-ras mutations, were
insensitive to TPA for the induction of apoptosis (Fig. 4). However,
the question of how OA, which selectively may expand cells with
Ha-ras mutations in intact mouse skin in vivo, induces
apoptosis in vitro of cell lines that contain ras mutations, is critical to the interpretation of present results (Hennings et al.,
1992
; Fujiki and Suganuma, 1993
). The role of ras mutations in mouse skin tumor formation by the inhibitors of PP 1 and 2A needs
reevaluation. We hypothesize that the initiated cells, which escape
OA-induced apoptosis and proliferate to form papillomas and carcinomas,
have other genetic lesions in addition to Ha-ras mutations.
All epidermal cells, which have only Ha-ras mutations, undergo apoptosis during tumor promotion with OA. We now present results indicating that the proliferative signals of
ras-activated cells can be diverted toward apoptosis by
inhibition of PP1 and PP2A by OA.
OA-induced cell death was due to apoptosis and not the results of necrosis as confirmed by several criteria such as morphological characteristics, analysis of preapoptotic cells entering apoptosis by dual-colored (PI and Annexin V) flow cytometry, and DNA fragmentation by agarose gel electrophoresis (Figs. 1-3 and 6-8). OA-induced apoptosis appears to involve mitochondrial changes and DNA fragmentation (Fig. 2). It is clear from the results, using isogenic cell lines, that ras mutation imparts sensitivity to cells to OA-induced apoptosis (Figs. 1-3 and 6 and7). To obtain additional evidence to support the conclusion that ras mutation imparts sensitivity to cells to OA-induced apoptosis, we screened several established cell lines harboring mutations in either H-ras (T24 and 308) and K-ras genes (DLD-1, HCT116, Calu-6, SK-LU-1, and MIAPaCa2). The results illustrated in Fig. 9 clearly indicate that the sensitivity of several murine and human cell lines to OA-induced apoptosis correlated with the presence of mutation in the ras oncogene H or K. Because the concentrations of OA used in the present study inhibited both PP1 and PP2A (Figs. 11 and 12), the onset of apoptosis appears to link to the sustained phosphorylation of PP1 and PP2A substrates.
The role of functional p53 in determining cell's sensitivity to
OA-induced apoptosis has been inconsistent. In this context the reports
by Sheikh et al. (1996)
, and Boe et al. (1991)
are noteworthy. They
observed the induction of apoptosis by OA in breast cancer cell lines
with disrupted p53 function. However, others have proposed both
p53-independent and p53-dependent pathways in OA-induced apoptosis in
NIH3T3 (p53
/
) (Yan et al., 1997
) and rabbit lens epithelial cells
(Li et al., 1998
). Interestingly, we found that cell lines with or
without mutations in p53 were equally susceptible to OA-induced
apoptosis (Figs. 6 and 9), implying that OA-induced
G2-M arrest and apoptosis involves
p53-independent pathways.
The mechanisms by which the expression of H-ras up-regulates
PP2A activity (Fig. 11) are unknown. The native form of PP2A consists of A and C subunits that are considered to form the core of the enzyme. The C unit binds stably to the carboxyl terminal region of the
A subunit. The B subunit binds to the amino terminal region of the
A subunit. The B family has three members (B
, B
, and B
) (~55 kDa). The B' family consists of several isoforms
(~54-68 kDa), whereas the B" family has two members (72 and 130 kDa). The combination of B subunits to the core PP2A heterodimeric
complex gives rise to the several PP2A variants that exhibit substrate specificity. The B subunits act as targeting subunits that direct PP2A
to specific subcellular locations (Strack et al., 1998
). Ras-induced up-regulation of PP2A activity may be the result
of increased synthesis of PP2A subunits (A, C, and B) due to increased transcription or translation. PP2A activity is also regulated by
post-translational modification (methylation) of the catalytic subunit
of PP2A (Turowski et al., 1995
; Kloeker et al., 1997
). Ras
activation may up-regulate PP2A activity by increasing the production
of ceramide catalyzed by sphingomyelinase. The ceramide 2 has been
shown to activate PP2A activity (Galadari et al., 1998
).
The cell lines, treated in vivo with OA, inhibited both PP1 and PP2A
activity (Fig. 12). The mechanisms by which inhibition of PP1 and PP2A
activity lead to the induction of apoptosis in ras-activated
cells remains to be defined. OA-induced apoptosis preceded arrests
cells in the progression of G2-M phase (Table 3).
Entry into mitosis is triggered by the maturation promoting factor,
which is composed of cdk2 and cyclin B. In early
G2, the human cdc2 protein is phosphorylated on
tyrosine 15 and threonine 14 by Weel and Mik1 to inhibit its
activation. G2 to M progression requires
activation of cdc2 by dephosphorylation of cdc2 by the dual specificity
PP cdc25 (Draetta and Eckstein, 1997
). Cdc25C activity in
G2 phase is negatively regulated by PP2A. In
human cells, there are three cdk activating phosphatases (cdc25A,
cdc25B, and cdc25C). Cdc25A is expressed early in the
G1 phase of the cell cycle, whereas cdc25B and
cdc25C are expressed at the G2-M boundary
(Draetta and Eckstein, 1997
). It is likely that OA-induced G2-M arrest may be the result of inhibition of
cyclin B1 accumulation by OA (Table 4). However, the roles of other
cell cycle regulatory proteins such as other cyclins and
cyclin-dependent kinase inhibitors in OA-induced
G2-M arrest remain to be explored.
OA treatment leads to the production of tumor necrosis factor-
(TNF
) in BALB/c 3T3 cells (Komori et al., 1993
). TNF
is a
cytokine (molecular mass 17 kDa) and is produced mainly by
monocytes and/or macrophages. TNF
is implicated in various
biological processes such as immunoregulation, inflammation, cachexia
and mitogenesis. OA and TNF
have been shown to share similar effects
such as the induction of protein phosphorylation and the expression of
early response genes. TNF
, like OA, was found to be a tumor promoter (Guy et al., 1992
; Fujiki et al., 1997
). We also found that OA-induced apoptosis of human cell lines accompanied release of TNF
in the medium (D.R. and A.K.V., unpublished observations). The role of TNF
in OA-induced apoptosis is currently being investigated.
In summary, we have shown, using isogenic cell pairs (Figs. 1-3, 6, and 7) and other established cell lines (Fig. 9), that OA and other inhibitors of PP1 and PP2A (e.g., calyculin, tautomycin, dinophysitoxin, and microcystin) induce apoptosis in cell lines that harbor either H- or K-ras mutations. OA-mediated apoptosis does not appear to require the presence of wild-type p53 (Fig. 9). An overall survey of the basal levels of PP1 and PP2A indicates the presence of both enzymes at different levels in different cell lines (Fig. 11). However, H-ras mutation appears to affect the level of PP2A activity (Fig. 11). The results presented indicated that the cell survival signals imparted by the oncogenic ras can be diverted to cell death signals by inhibition of PP1 and PP2A activities. Thus, the PP1 and PP2A and their associated signaling molecules (e.g., hyperphosphorylated proteins and genes) may be potential targets for human cancer treatments.
| |
Acknowledgments |
|---|
We are thankful to Kevin Kwei for help with the experiment to detect the DNA ladder in the apoptotic cells.
| |
Footnotes |
|---|
Received February 1, 1999; Accepted June 11, 1999
This work was supported by the National Institute of Health Grant, CA 35368.
Send reprint requests to: Dr. Ajit K. Verma, Department of Human Oncology, K4/532, CSC, 600 Highland Avenue, University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792. E-mail: akverma{at}facstaff.wisc.edu.
| |
Abbreviations |
|---|
PP, protein phosphatase;
TPA, 12-O-tetradecanoylphorbol-13-acetate;
OA, Okadaic acid;
TNF
, tumor necrosis factor-
;
UEPC, uroepithelial cell.
| |
References |
|---|
|
|
|---|
gene expression by the okadaic acid class tumor promoters.
Environ Carcino Ecotox Revs
15:
1-40.This article has been cited by other articles:
![]() |
K. Horiguchi, T. Shirakihara, A. Nakano, T. Imamura, K. Miyazono, and M. Saitoh Role of Ras Signaling in the Induction of Snail by Transforming Growth Factor-{beta} J. Biol. Chem., January 2, 2009; 284(1): 245 - 253. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Aziz, N. E. Dreckschmidt, and A. K. Verma Plumbagin, a Medicinal Plant-Derived Naphthoquinone, Is a Novel Inhibitor of the Growth and Invasion of Hormone-Refractory Prostate Cancer Cancer Res., November 1, 2008; 68(21): 9024 - 9032. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Castro, I. Ferrer, A. Cascon, M. V. Guijarro, M. Lleonart, S. R. y Cajal, J. F.M. Leal, M. Robledo, and A. Carnero PPP1CA contributes to the senescence program induced by oncogenic Ras Carcinogenesis, March 1, 2008; 29(3): 491 - 499. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. R. Monks, S. Liu, Y. Xu, H. Yu, A. S. Bendelow, and J. A. Moscow Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1- and OATP1B3-expressing HeLa cells Mol. Cancer Ther., February 1, 2007; 6(2): 587 - 598. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Silverstein, C. A. Barrow, A. J. Davis, and M. C. Mumby Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits PNAS, April 2, 2002; 99(7): 4221 - 4226. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Gjoerup, D. Zaveri, and T. M. Roberts Induction of p53-Independent Apoptosis by Simian Virus 40 Small t Antigen J. Virol., October 1, 2001; 75(19): 9142 - 9155. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. C. Crawford, B. Fingleton, M. D. Gustavson, N. Kurpios, R. A. Wagenaar, J. A. Hassell, and L. M. Matrisian The PEA3 Subfamily of Ets Transcription Factors Synergizes with {beta}-Catenin-LEF-1 To Activate Matrilysin Transcription in Intestinal Tumors Mol. Cell. Biol., February 15, 2001; 21(4): 1370 - 1383. [Abstract] [Full Text] |
||||
![]() |
A. A. Adjei, J. N. Davis, C. Erlichman, P. A. Svingen, and S. H. Kaufmann Comparison of Potential Markers of Farnesyltransferase Inhibition Clin. Cancer Res., June 1, 2000; 6(6): 2318 - 2325. [Abstract] [Full Text] |
||||
![]() |
A. M. Silverstein, C. A. Barrow, A. J. Davis, and M. C. Mumby Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits PNAS, April 2, 2002; 99(7): 4221 - 4226. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||